Effects of eicosapentaenoic acid and docosahexaenoic acid on low-density lipoprotein cholesterol and other lipids: A review

Journal of Clinical Lipidology

Volumn 6, Issue 1, 2012, Pages 5-18

  Jacobson, Terry A ^a   Glickstein, Sara B ^b   Rowe, Jonathan D ^c   Soni, Paresh N ^d  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Rete Biomedical Communications Corp   (United States)

^c Dignity Sciences Ltd   (Ireland)

^d Amarin Pharma Inc   (United States)

Author keywords

Apo B; Cardiovascular disease; DHA; EPA; LDL C; Omega 3 fatty acids

Indexed keywords

DOCOSAHEXAENOIC ACID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; ICOSAPENTAENOIC ACID; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OMEGA 3 FATTY ACID; OMEGA 3 FATTY ACID ESTER; PLACEBO; TRIACYLGLYCEROL;

CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; COMPARATIVE STUDY; DATA ANALYSIS; DRUG EFFECT; HUMAN; LIPID BLOOD LEVEL; MEDICAL DOCUMENTATION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW;

CHOLESTEROL; CHOLESTEROL, LDL; DOCOSAHEXAENOIC ACIDS; EICOSAPENTAENOIC ACID; HUMANS; HYPERLIPIDEMIAS; HYPOLIPIDEMIC AGENTS; LIPID METABOLISM; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 84856179128     PISSN: 19332874     EISSN: 18764789     Source Type: Journal    
DOI: 10.1016/j.jacl.2011.10.018     Document Type: Review

References (65)

1. J.D. Cohen, M.J. Cziraky, and Q. Cai 30-year trends in serum lipids among United States adults: results from the National Health and Nutrition Examination Surveys II, III, and 1999-2006 Am J Cardiol 106 2010 969 975
2. P.M. Kris-Etherton, W.S. Harris, L.J. Appel American Heart Association Nutrition Committee Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease Circulation 106 2002 2747 2757 (Pubitemid 35364932)
3. W.S. Harris, M. Miller, A.P. Tighe, M.H. Davidson, and E.J. Schaefer Omega-3 fatty acids and coronary heart disease risk: clinical and mechanistic perspectives Atherosclerosis 197 2008 12 24
4. M. Yokoyama, H. Origasa, and M. Matsuzaki Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis Lancet 369 2007 1090 1098 (Pubitemid 46483662)
5. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico Lancet 354 1999 447 455
6. ® (omega-3-acid ethyl esters) [US full prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; 2009. Available at: http://us.gsk.com/products/assets/us-lovaza.pdf. Accessed March 23, 2011.
7. ® [Complete prescribing information]. Update (Version 5). Tokyo, Japan: Mochida Pharmaceutical; January 2007.
8. W.S. Harris, H.N. Ginsberg, and N. Arunakul Safety and efficacy of Omacor in severe hypertriglyceridemia J Cardiovasc Risk 4 1997 385 391 (Pubitemid 28078682)
9. H.J. Pownall, D. Brauchi, and C. Kilin Correlation of serum triglyceride and its reduction by omega-3 fatty acids with lipid transfer activity and the neutral lipid compositions of high-density and low-density lipoproteins Atherosclerosis 143 1999 285 297 (Pubitemid 29166909)
10. Center for Drug Evaluation and Research. Approval Package for: 21-654 (Omacor/Lovaza). Statistical Review; 2004. Available at: http://www.accessdata. fda.gov/drugsatfda-docs/nda/2004/21-654-Omacor-AdminCorres-P1.pdf. Accessed June 24, 2011.
11. K.C. Maki, M.R. Dicklin, M.H. Davidson, R.T. Doyle, C.M. Ballantyne COMBination of prescription Omega-3 with Simvastatin (COMBOS) Investigators Baseline lipoprotein lipids and low-density lipoprotein cholesterol response to prescription omega-3 acid ethyl ester added to simvastatin therapy Am J Cardiol 105 2010 1409 1412
12. M.H. Davidson, E.A. Stein, and H.E. Bays Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study Clin Ther 29 2007 1354 1367 (Pubitemid 47348116)
13. H.E. Bays, K.C. Maki, and J. McKenney Long-term up to 24-month efficacy and safety of concomitant prescription omega-3-acid ethyl esters and simvastatin in hypertriglyceridemic patients Curr Med Res Opin 26 2010 907 915
14. Center for Drug Evaluation and Research. Application Number: 21-853, 21654s016, (Omacor). Statistical Review and Evaluation: Clinical Studies, Omacor (omega-3 acid ethyl ester) Capsules, 4 grams/day; 2007. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/nda/2007/021853s000;%20021654s016- StatR.pdf. Accessed June 24, 2011.
15. C. Baigent, A. Keech, and P.M. Kearney Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins Lancet 366 2005 1267 1278
16. E.M. Balk, A.H. Lichtenstein, M. Chung, B. Kupelnick, P. Chew, and J. Lau Effects of omega-3 fatty acids on serum markers of cardiovascular disease risk: a systematic review Atherosclerosis 189 2006 19 30 (Pubitemid 44468073)
17. J. Hartweg, A.J. Farmer, R.R. Holman, and A. Neil Potential impact of omega-3 treatment on cardiovascular disease in type 2 diabetes Curr Opin Lipidol 20 2009 30 38
18. E.L. Lien Toxicology and safety of DHA Prostaglandins Leukot Essent Fatty Acids 81 2009 125 132
19. Haney EM, Huffman LH, Bougatsos C, et al. Screening for lipid disorders in children and adolescents; Systematic evidence review for the U.S. Preventive Services Task Force (evidence synthesis). No. 47. Rockville, MD: Agency for Healthcare Research and Quality, US Department of Health and Human Services; AHRQ Publication No. 07-0598-EF-1; July 2007. Available at: http://www. uspreventiveservicestaskforce.org/uspstf07/chlipid/chlipidsyn.pdf. Accessed March 23, 2011.
20. W.T. Friedewald, R.I. Levy, and D.S. Fredrickson Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge Clin Chem 18 1972 499 502
21. S. Egert, F. Kannenberg, V. Somoza, H.F. Erbersdobler, and U. Wahrburg Dietary alpha-linolenic acid, EPA, and DHA have differential effects on LDL fatty acid composition but similar effects on serum lipid profiles in normolipidemic humans J Nutr 139 2009 861 868
22. S. Grimsgaard, K.H. Bonaa, J.B. Hansen, and A. Nordøy Highly purified eicosapentaenoic acid and docosahexaenoic acid in humans have similar triacylglycerol-lowering effects but divergent effects on serum fatty acids Am J Clin Nutr 66 1997 649 659 (Pubitemid 27366792)
23. T.A. Mori, V. Burke, I.B. Puddey, G.F. Watts, D.N. O'Neal, J.D. Best, and L.J. Beilin Purified eicosapentaenoic and docosahexaenoic acids have differential effects on serum lipids and lipoproteins, LDL particle size, glucose, and insulin in mildly hyperlipidemic men Am J Clin Nutr 71 2000 1085 1094 (Pubitemid 30230554)
24. P. Nestel, H. Shige, S. Pomeroy, M. Cehun, M. Abbey, and D. Raederstorff The n-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid increase systemic arterial compliance in humans Am J Clin Nutr 76 2002 326 330 (Pubitemid 34804052)
25. Y. Park, and W.S. Harris Omega-3 fatty acid supplementation accelerates chylomicron triglyceride clearance J Lipid Res 44 2003 455 463 (Pubitemid 37279692)
26. R.J. Woodman, T.A. Mori, V. Burke, I.B. Puddey, G.F. Watts, and L.J. Beilin Effects of purified eicosapentaenoic and docosahexaenoic acids on glycemic control, blood pressure, and serum lipids in type 2 diabetic patients with treated hypertension Am J Clin Nutr 76 2002 1007 1015 (Pubitemid 35244671)
27. M. Ando, T. Sanaka, and H. Nihei Eicosapentanoic acid reduces plasma levels of remnant lipoproteins and prevents in vivo peroxidation of LDL in dialysis patients J Am Soc Nephrol 10 1999 2177 2184 (Pubitemid 29453496)
28. T. Kurabayashi, M. Okada, and K. Tanaka Eicosapentaenoic acid effect on hyperlipidemia in menopausal Japanese women. The Niigata Epadel Study Group Obstet Gynecol 96 2000 521 528
29. N. Satoh, A. Shimatsu, and K. Kotani Purified eicosapentaenoic acid reduces small dense LDL, remnant lipoprotein particles, and C-reactive protein in metabolic syndrome Diabetes Care 30 2007 144 146 (Pubitemid 46061295)
30. K. Tanaka, Y. Ishikawa, and M. Yokoyama Reduction in the recurrence of stroke by eicosapentaenoic acid for hypercholesterolemic patients: subanalysis of the JELIS trial Stroke 39 2008 2052 2058
31. J.J. Agren, O. Hänninen, and A. Julkunen Fish diet, fish oil and docosahexaenoic acid rich oil lower fasting and postprandial plasma lipid levels Eur J Clin Nutr 50 1996 765 771 (Pubitemid 26393469)
32. J.A. Conquer, and B.J. Holub Supplementation with an algae source of docosahexaenoic acid increases (n-3) fatty acid status and alters selected risk factors for heart disease in vegetarian subjects J Nutr 126 1996 3032 3039 (Pubitemid 27023877)
33. J.A. Conquer, and B.J. Holub Effect of supplementation with different doses of DHA on the levels of circulating DHA as non-esterified fatty acid in subjects of Asian Indian background J Lipid Res 39 1998 286 292 (Pubitemid 28100666)
34. M.H. Davidson, K.C. Maki, J. Kalkowski, E.J. Schaefer, S.A. Torri, and K.B. Drennan Effects of docosahexaenoic acid on serum lipoproteins in patients with combined hyperlipidemia: a randomized, double-blind, placebo-controlled trial J Am Coll Nutr 16 1997 236 243 (Pubitemid 27237527)
35. M.M. Engler, M.B. Engler, and M. Malloy Docosahexaenoic acid restores endothelial function in children with hyperlipidemia: results from the EARLY study Int J Clin Pharmacol Ther 42 2004 672 679 (Pubitemid 39625126)
36. J. Geppert, V. Kraft, H. Demmelmair, and B. Koletzko Microalgal docosahexaenoic acid decreases plasma triacylglycerol in normolipidaemic vegetarians: a randomised trial Br J Nutr 95 2006 779 786
37. D.S. Kelley, D. Siegel, M. Vemuri, and B.E. Mackey Docosahexaenoic acid supplementation improves fasting and postprandial lipid profiles in hypertriglyceridemic men Am J Clin Nutr 86 2007 324 333 (Pubitemid 47256914)
38. K.C. Maki, M.E. Van Elswyk, and D. McCarthy Lipid responses to a dietary docosahexaenoic acid supplement in men and women with below average levels of high density lipoprotein cholesterol J Am Coll Nutr 24 2005 189 199 (Pubitemid 41201962)
39. T.A. Sanders, K. Gleason, B. Griffin, and G.J. Miller Influence of an algal triacylglycerol containing docosahexaenoic acid (22:6 n-3) and docosapentaenoic acid (22:5 n-6) on cardiovascular risk factors in healthy men and women Br J Nutr 95 2006 525 531
40. K.D. Stark, and B.J. Holub Differential eicosapentaenoic acid elevations and altered cardiovascular disease risk factor responses after supplementation with docosahexaenoic acid in postmenopausal women receiving and not receiving hormone replacement therapy Am J Clin Nutr 79 2004 765 773 (Pubitemid 41103876)
41. H.E. Theobald, P.J. Chowienczyk, R. Whittall, S.E. Humphries, and T.A. Sanders LDL cholesterol-raising effect of low-dose docosahexaenoic acid in middle-aged men and women Am J Clin Nutr 79 2004 558 563 (Pubitemid 41103897)
42. W.H. Wu, S.C. Lu, T.F. Wang, H.J. Jou, and T.A. Wang Effects of docosahexaenoic acid supplementation on blood lipids, estrogen metabolism, and in vivo oxidative stress in postmenopausal vegetarian women Eur J Clin Nutr 60 2006 386 392 (Pubitemid 43354933)
43. J.G. Robinson, S. Wang, B.J. Smith, and T.A. Jacobson Meta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart risk J Am Coll Cardiol 53 2009 316 322
44. M.R. Law, N.J. Wald, and A.R. Rudnicka Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis Br Med J 326 2003 1423 1427 (Pubitemid 36776152)
45. A.L. Gould, J.E. Rossown, N.C. Santanello, J.F. Heyse, and C.D. Furberg Cholesterol reduction yields clinical benefit: impact of statin trials Circulation 97 1998 946 952 (Pubitemid 28125465)
46. D.J. Gordon, J.L. Probstfield, and R.J. Garrison High density lipoprotein cholesterol and cardiovascular disease: four prospective American studies Circulation 79 1989 8 15 (Pubitemid 19043669)
47. T.A. Mori, and R.J. Woodman The independent effects of eicosapentaenoic acid and docosahexaenoic acid on cardiovascular risk factors in humans Curr Opin Clin Nutr Metab Care 9 2006 95 104 (Pubitemid 44090031)
48. A.S. Ryan, M.A. Keske, J.P. Hoffman, and E.B. Nelson Clinical overview of algal-docosahexaenoic acid: effects on triglyceride levels and other cardiovascular risk factors Am J Ther 16 2009 183 192
49. E.J. Schaefer, I.B. Asztalos, and J.A. Gleason Effects of eicosapentaenoic acid, docosahexaenoic acid, and olive oil on cardiovascular disease risk factors [abstract 20007] Circulation 122 2010 A20007
50. H.E. Bays, A.P. Tighe, R. Sadovsky, and M.H. Davidson Prescription omega-3 fatty acids and their lipid effects: physiologic mechanisms of action and clinical implications Expert Rev Cardiovasc Ther 6 2008 391 409
51. G. Lu, S.L. Windsor, and W.S. Harris Omega-3 fatty acids alter lipoprotein subfraction distributions and the in vitro conversion of very low density lipoproteins to low density lipoproteins J Nutr Biochem 10 1999 151 158 (Pubitemid 29101639)
52. R.K. Berge, L. Madsen, H. Vaagenes, K.J. Tronstad, M. Göttlicher, and A.C. Rustan In contrast with docosahexaenoic acid, eicosapentaenoic acid and hypolipidaemic derivatives decrease hepatic synthesis and secretion of triacylglycerol by decreased diacylglycerol acyltransferase activity and stimulation of fatty acid oxidation Biochem J 343 Pt 1 1999 191 197 (Pubitemid 29473895)
53. M.J. Chapman, W. Le Goff, M. Guerin, and A. Kontush Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors Eur Heart J 31 2010 149 164
54. R. Hirano, O. Igarashi, K. Kondo, H. Itakura, and A. Matsumoto Regulation by long-chain fatty acids of the expression of cholesteryl ester transfer protein in HepG2 cells Lipids 36 2001 401 406 (Pubitemid 32433876)
55. S. Nozaki, Y. Matsuzawa, K. Hirano, N. Sakai, M. Kubo, and S. Tarui Effects of purified eicosapentaenoic acid ethyl ester on plasma lipoproteins in primary hypercholesterolemia Int J Vitam Nutr Res 62 1992 256 260
56. H. Campos, L.A. Moye, S.P. Glasser, M.J. Stampfer, and F.M. Sacks Low-density lipoprotein size, pravastatin treatment, and coronary events JAMA 286 2001 1468 1474 (Pubitemid 33015503)
57. S. Mora, M. Szklo, and J.D. Otvos LDL particle subclasses, LDL particle size, and carotid atherosclerosis in the Multi-Ethnic Study of Atherosclerosis (MESA) Atherosclerosis 192 2007 211 217 (Pubitemid 46602300)
58. J. Hannah, S. Kataoka, K. Yamane, G. Schectman, S. Kaul, and B.V. Howard Effect of dietary fatty acids on LDL binding Ann N Y Acad Sci 683 1993 178 182 (Pubitemid 23236665)
59. S. Lindsey, A. Pronczuk, and K.C. Hayes Low density lipoprotein from humans supplemented with n-3 fatty acids depresses both LDL receptor activity and LDLr mRNA abundance in HepG2 cells J Lipid Res 33 1992 647 658
60. G.S. Rambjør, A.I. Walen, S.L. Windsor, and W.S. Harris Eicosapentaenoic acid is primarily responsible for hypotriglyceridemic effect of fish oil in humans Lipids 31 Suppl 1996 S45 S49
61. P.D. Roach, A.M. Kambouris, R.P. Trimble, D.L. Topping, and P.J. Nestel The effects of dietary fish oil on hepatic high density and low density lipoprotein receptor activities in the rat FEBS Lett 222 1987 159 162
62. G. Schectman, L.E. Boerboom, J. Hannah, B.V. Howard, R.A. Mueller, and A.H. Kissebah Dietary fish oil decreases low-density-lipoprotein clearance in nonhuman primates Am J Clin Nutr 64 1996 215 221 (Pubitemid 26250842)
63. M.E. Surette, J. Whelan, G.P. Lu, K.S. Broughton, and J.E. Kinsella Dependence on dietary cholesterol for n-3 polyunsaturated fatty acid-induced changes in plasma cholesterol in the Syrian hamster J Lipid Res 33 1992 263 271
64. R.E. Morton Specificity of lipid transfer protein for molecular species of cholesteryl ester J Lipid Res 27 1986 523 529 (Pubitemid 16051151)
65. P.J. Nestel Effects of N-3 fatty acids on lipid metabolism Ann Rev Nutr 10 1990 149 167